[A23-62] Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V

Last updated 02.10.2023

Project no.:
A23-62

Commission:
Commission awarded on 03.07.2023 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Muscles, bones and joints

Indication:

Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or demonstrated by magnetic resonance imaging

Result of dossier assessment:
  • Patients who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs: added benefit not proven
  • Patients who have responded inadequately or are intolerant to prior therapy with biological antirheumatic drugs: added benefit not proven
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form